Biogen buys Tysabri from Elan for $3.25bn


US biotech Biogen Idec is to pay $3.25 billion (£2 billion) to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis (MS).

The drug is currently marketed jointly by the two companies, with profits split evenly. It generated $1.6 billion in sales in 2012, up 8% compared with 2011, and accounted for almost all the sales at Elan.

Under the terms, Biogen Idec will pay $3.25 billion up front in order to take full ownership of the blockbuster drug and agree to make future payments linked to sales.

The deal ‘provides for a meaningful de-risking of the business’, said Elan chief executive Kelly Martin. ‘As we move through 2013 and beyond, the close of the Tysabri transaction gives us strategic flexibility to add to the shareholder value proposition and investment thesis by enabling continued prudent and risk justified investment in our pipeline, selectively adding commercial and clinical assets, and exploring the return of capital to shareholders at the appropriate time and in the right manner.’


Related Content

Talk of a $6.6bn deal for Elan

27 February 2013 Business

news image

Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights

Perrigo bags Elan and its bargain Irish tax rates

31 July 2013 Business

news image

$8.6bn deal ends Elan’s takeover battle with Royalty Pharma

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

First flexible graphene display paves the way for folding electronics

11 September 2014 News and Analysis

news image

Team behind the bendy e-reader display hope to have a full colour graphene-based smartphone style screen within a year

Most Commented

Does life play dice?

3 September 2014 The Crucible

news image

Philip Ball wonders whether life evolved to exploit quantum phenomena, or if it’s just in our nature

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow